ISLT / Islet Sciences, Inc. - Documents déposés auprès de la SEC, rapport annuel, procuration

ISLT / Islet Sciences, Inc. / Typenex Co-Investment, LLC - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Islet Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46467R109 (CUSIP Number) July 07, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Current Report

Blueprint SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2016 Islet Sciences, Inc. Nevada 001-34048 87-0531751 (State or other jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 1822 E Route 6

CONFIDENTIAL SETTLEMENT AGREEMENT AND GENERAL RELEASE

EX-10 2 isltex101.htm MATERIAL CONTRACTS Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT AND GENERAL RELEASE This Settlement Agreement and General Release Agreement (the “Agreement”) is made by and between Islet Sciences, Inc (“Islet”) on the one hand, and Progenitor Cell Therapy, LLC (“PCT” and, together with Islet, the “Parties”), For purposes of the Agreement, the term “Islet” shall mean collect

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Untitled Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2016 Islet Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2016 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commissio

ISLET SCIENCES, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

isltex101.htm Exhibit 10.1 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY A

Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2015 Islet Sciences, Inc.

EX-3.1

isltex31.htm Exhibit 3.1

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (I

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2015 Islet Sciences, Inc.

CONSULTING AGREEMENT

isltex101.htm Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made and entered into effective as of October 10, 2015, between David E. Wilder (?Wilder? or ?Consultant?), an individual whose address is 4160 Beech Ave., Yorba Linda CA 92886 and Islet Sciences, Inc., a Publicly traded company, (Ticker: ISLT) (the ?Company? or ?ISLT?), a corporation duly organized and

CONSULTING AGREEMENT

isltex102.htm Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made and entered into effective as of August, 2015 between Larry K. Ellingson (?Ellingson? or ?Consultant?), an individual whose address is 9844 N. Red Bluff Drive, Fountain Hills, AZ 85268 and Islet Sciences, Inc., a Publicly traded company, (Ticker: ISLT) (the ?Company? or ?ISLT?), a corporation duly o

Islet Sciences Appoints Chief Financial and Chief Operating Officer Seasoned Financial Executive, David E. Wilder, Joins Biopharmaceutical Company

EX-99.1 4 isltex991.htm PRESS RELEASE Exhibit 99.1 Islet Sciences Appoints Chief Financial and Chief Operating Officer Seasoned Financial Executive, David E. Wilder, Joins Biopharmaceutical Company NEW YORK, NY-(Marketwired – Oct 21, 2015) - Islet Sciences, Inc. (OTCQB: ISLT) ("Islet Sciences"), a biopharmaceutical company focused on developing new technologies and medicines for the early detectio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IR

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS E

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission F

1

isltex101.htm Exhibit 10.1 1 2 3

Islet Sciences CURRENT REPORT (Current Report/Significant Event)

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission Fi

FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

EX-10.1 2 isltex101.htm AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 Execution Version FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Fifth Amendment”) is dated as of the 6th day of July, 2015 (the “Fifth Amendment Date”) by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered

FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

EX-10.1 2 isltex101.htm FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BETWEEN THE COMPANY AND BRIGHTHAVEN VENTURES, L.L.C. Exhibit 10.1 Execution Version FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Fourth Amendment”) is dated as of the 29th day of June, 2015 (the “Fourth Amendment Date”) by and between Brighthaven Ventures, L.L.C.,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2015 Islet Sciences, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS E

THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

ex101.htm Exhibit 10.1 Execution Version THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this ?Third Amendment?) is dated as of the 22nd day of June, 2015 (the ?Third Amendment Date?) by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Trian

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

EX-10.1 2 isltex101.htm AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 Execution Version SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Second Amendment”) is dated as of the 14th day of June, 2015 (the “Second Amendment Date”) by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its regist

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission F

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K 155 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS Employer of I

AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

isltex101.htm Exhibit 10.1 Execution Version AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this ?Amendment?) is dated as of the 29th day of May, 2015 (the ?Amendment Date?) by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 (?

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission

CONVERTIBLE PROMISSORY NOTE Effective Date: April 24, 2015 U.S. $170,000.00

Exhibit 4.2 CONVERTIBLE PROMISSORY NOTE Effective Date: April 24, 2015 U.S. $170,000.00 FOR VALUE RECEIVED, Islet Sciences, Inc., a Nevada corporation (“Borrower”), promises to pay to Typenex Co-Investment, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $170,000.00 and any interest, fees, charges, and late fees on the date that is ten (10) months after the Purchase

Securities Purchase Agreement

EX-4.1 2 isltex41.htm SECURITIES PURCHASE AGREEMENT Exhibit 4.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of April 24, 2015, is entered into by and between Islet Sciences, Inc., a Nevada corporation (“Company”), and Typenex Co-Investment, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor ar

ISLET SCIENCES, INC. DIRECTOR AGREEMENT

isltex101.htm Exhibit 10.1 ISLET SCIENCES, INC. DIRECTOR AGREEMENT THIS AGREEMENT (the "Agreement") is made as of the day of 2015 and is by and between Islet Sciences, Inc., a Nevada corporation (hereinafter referred to as the "Company"), and (hereinafter referred to as the "Director"). WHEREAS, it is essential to the Company to attract and retain accomplished and capable individuals to serve on t

ISLET SCIENCES, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

isltex43.htm Exhibit 4.3 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APP

Islet Sciences QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2015 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 ————

Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate

EX-99.1 4 isltex991.htm PRESS RELEASE Exhibit 99.1 Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate RALEIGH, North Carolina March, 3 2015 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today that it has entered into a license agree

Note: Throughout this document, certain confidential material contained herein has been omitted and has been separately filed with the Commission. Each omission has been marked with an [***].

EX-10.1 2 isltex101.htm EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 Note: Throughout this document, certain confidential material contained herein has been omitted and has been separately filed with the Commission. Each omission has been marked with an [***]. EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is dated as of the 3rd day of March, 2015 (the “Execution Date”

TERMINATION AGREEMENT

Exhibit 10.2 TERMINATION AGREEMENT This TERMINATION AGREEMENT dated as of March 3, 2015 (this “Agreement”) is entered into by and among Islet Sciences, Inc., a Nevada corporation (“Islet”), Brighthaven Ventures, L.L.C., a North Carolina limited liability company (“BHV”), Avogenx, Inc., a Delaware corporation and a direct wholly owned subsidiary of Islet (“Holdco”), Islet Merger Sub, Inc., a Nevada

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

islt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2015 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS E

Islet Sciences, Inc. Confirms Issuance of U.S. Patent for using SGLT2 inhibitors to treat NASH/NAFLD

isltex992.htm Exhibit 99.2 Islet Sciences, Inc. Confirms Issuance of U.S. Patent for using SGLT2 inhibitors to treat NASH/NAFLD RALEIGH, North Carolina, March 5, 2015 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced today a Notice of Claims Allowance for the U.S. Patent Application No. 12/5

Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH) Islet Sciences’ William Wilkison, Ph.D. to Present Efficacy Results at the 2015 International Liver Conference

Exhibit 99.3 Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH) Islet Sciences’ William Wilkison, Ph.D. to Present Efficacy Results at the 2015 International Liver Conference RALEIGH, North Carolina March, 9 2015 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2014 TRANSITION REPORT PURSUANT TO S

[ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2014 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 —————

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2014 Islet Sciences, Inc.

Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes -- Key Studies Provide Rationale for Current Biphasic Drug Formulation --

Exhibit 99.1 Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes - Key Studies Provide Rationale for Current Biphasic Drug Formulation - Raleigh, NC, October 23, 2014 - Islet Sciences, Inc. (OTCQB: ISLT) (“Islet Sciences”), a biopharmaceutical company developing new medicines and technologies for the treatment of meta

ISLT / Islet Sciences, Inc. 425 - Merger Prospectus - CURRENT REPORT

425 1 islt8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 23, 2014 Islet Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Inco

Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes -- Key Studies Provide Rationale for Current Biphasic Drug Formulation --

Exhibit 99.1 Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes - Key Studies Provide Rationale for Current Biphasic Drug Formulation - Raleigh, NC, October 23, 2014 - Islet Sciences, Inc. (OTCQB: ISLT) (“Islet Sciences”), a biopharmaceutical company developing new medicines and technologies for the treatment of meta

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 23, 2014 Islet Sciences, Inc.

Islet Sciences, Inc., Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate

Exhibit 99.1 Islet Sciences, Inc., Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate Raleigh, NC, October 6, 2014 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced that its merger partner, BH

Islet Sciences, Inc., Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate

Exhibit 99.1 Islet Sciences, Inc., Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate Raleigh, NC, October 6, 2014 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced that its merger partner, BH

ISLT / Islet Sciences, Inc. 425 - Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2014 Islet Sciences, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2014 Islet Sciences, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2014 Islet Sciences, Inc.

Islet Sciences and BHV Pharma Enter into Merger Agreement; Combined Company to be Named Avogenx, Inc.

Exhibit 99.1 Islet Sciences and BHV Pharma Enter into Merger Agreement; Combined Company to be Named Avogenx, Inc. Raleigh, NC, October 1, 2014 - Islet Sciences, Inc. (OTCQB: ISLT) (“Islet Sciences”), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma (“BHV”), a privately held pharmaceutic

Islet Sciences and BHV Pharma Enter into Merger Agreement; Combined Company to be Named Avogenx, Inc.

Exhibit 99.1 Islet Sciences and BHV Pharma Enter into Merger Agreement; Combined Company to be Named Avogenx, Inc. Raleigh, NC, October 1, 2014 - Islet Sciences, Inc. (OTCQB: ISLT) (“Islet Sciences”), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma (“BHV”), a privately held pharmaceutic

VOTING AGREEMENT

EX-10.1 3 onceex101.htm VOTING AGREEMENT Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of , 2014, by and between Islet Sciences, Inc., a Nevada corporation (“Company”) and the person whose name appears on the signature page hereto (“Stockholder”). RECITALS A. On , 2014, Brighthaven Ventures, L.L.C., a North Carolina limited liability company (“B

AGREEMENT AND PLAN OF MERGER dated as of September 30, 2014 ISLET SCIENCES, INC., BRIGHTHAVEN VENTURES, L.L.C., AVOGENX, INC., ISLET MERGER SUB, INC., THE MEMBERS OF BRIGHTHAVEN VENTURES, L.L.C.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of September 30, 2014 among ISLET SCIENCES, INC., BRIGHTHAVEN VENTURES, L.L.C., AVOGENX, INC., ISLET MERGER SUB, INC., and THE MEMBERS OF BRIGHTHAVEN VENTURES, L.L.C. 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 4 ARTICLE II THE ACQUISITIONS 9 2.1 Organization of Holdco. 9 2.2 Organization of Islet Merger Sub. 9 2.3 The Acquisitions. 9 2.4 Effective T

VOTING AGREEMENT

Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of , 2014, by and between Islet Sciences, Inc., a Nevada corporation (“Company”) and the person whose name appears on the signature page hereto (“Stockholder”). RECITALS A. On , 2014, Brighthaven Ventures, L.L.C., a North Carolina limited liability company (“BHV”), each of the members of BHV (the “BH

AGREEMENT AND PLAN OF MERGER dated as of September 30, 2014 ISLET SCIENCES, INC., BRIGHTHAVEN VENTURES, L.L.C., AVOGENX, INC., ISLET MERGER SUB, INC., THE MEMBERS OF BRIGHTHAVEN VENTURES, L.L.C.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of September 30, 2014 among ISLET SCIENCES, INC., BRIGHTHAVEN VENTURES, L.L.C., AVOGENX, INC., ISLET MERGER SUB, INC., and THE MEMBERS OF BRIGHTHAVEN VENTURES, L.L.C. 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 4 ARTICLE II THE ACQUISITIONS 9 2.1 Organization of Holdco. 9 2.2 Organization of Islet Merger Sub. 9 2.3 The Acquisitions. 9 2.4 Effective T

ISLT / Islet Sciences, Inc. 425 - Merger Prospectus - 425

Filed by Islet Sciences, Inc. Commission File No. 001-34048 Pursuant to Rule 425 under the Securities Act of 1933 Islet Sciences and BHV Pharma Enter into Merger Agreement; Combined Company to be Named Avogenx, Inc. Raleigh, NC, October 1, 2014 - Islet Sciences, Inc. (OTCQB: ISLT) (“Islet Sciences”), a biopharmaceutical company developing new medicines and technologies for the treatment of metabol

ISLT / Islet Sciences, Inc. 425 - Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2014 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2014 TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2014 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 ——————— Is

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation Islet Sciences, Inc. Delaware DiaKine Therapeutics, Inc. Delaware

CODE OF BUSINESS CONDUCT AND ETHICS

Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS Summary of Policy This Code of Business Conduct and Ethics applies to all employees, officers and directors of Islet Sciences, Inc. and its subsidiaries. We expect all of our employees, officers and directors to act in accordance with the highest standards of personal and professional integrity in all aspects of their activities, to comply with all

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34048 Islet Sciences, Inc. (Exact na

ISLT / Islet Sciences, Inc. / SCHONINGER RICHARD - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2014 Islet Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2014 Islet Sciences, Inc.

Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2014 Islet Sciences, Inc.

ISLET SCIENCES, INC. DIRECTOR AGREEMENT

Exhibit 10.2 ISLET SCIENCES, INC. DIRECTOR AGREEMENT THIS AGREEMENT (the "Agreement") is made as of the day of March 2014 and is by and between Islet Sciences, Inc., a Nevada corporation (hereinafter referred to as the "Company"), and Michael Luther (hereinafter referred to as the "Director"). WHEREAS, it is essential to the Company to attract and retain accomplished and capable individuals to ser

Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH

Exhibit 99.1 Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH RALEIGH, NC-(Marketwired – March 13, 2014) - Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma (“BHV”). BHV is a privately held pharmaceutical c

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2014 Islet Sciences, Inc.

Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors

Exhibit 99.2 Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors RALEIGH, NC (March 14, 2014) - Islet Sciences, Inc. (OTCBB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet’s Board of Directors. “Dr. Luther has deep experience in drug discovery and development, and bring

Brighthaven Ventures L.L.C./Islet Sciences, Inc. BINDING LETTER OF INTENT For the Acquisition of Brighthaven Ventures, L.L.C.

Exhibit 10.1 March 12, 2014 Page 1 Brighthaven Ventures L.L.C./Islet Sciences, Inc. BINDING LETTER OF INTENT For the Acquisition of Brighthaven Ventures, L.L.C. This Letter of Intent (this “Letter of Intent”) sets forth the agreement of the parties hereto for Islet Sciences, Inc. (together with any newly organized parent company of Islet Sciences, Inc. utilized in a restructuring of Islet Sciences

ISLET SCIENCES, INC. SUBSCRIPTION AGREEMENT

Exhibit 10.1 ISLET SCIENCES, INC. SUBSCRIPTION AGREEMENT As of , 201 Mr. Joel Perlin Vice-President Islet Sciences, Inc. 641 Lexington Avenue, 6th Floor New York, New York 10022 1. Subscription; Escrow Arrangement. (a) The undersigned subscriber (the “Subscriber”) hereby irrevocably subscribes for and agrees to purchase the number of shares (the “Shares”) of the Company’s common stock, par value $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2014 TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2014 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 ————

ISLET SCIENCES, INC. DIRECTOR AGREEMENT

Exhibit 10.1 ISLET SCIENCES, INC. DIRECTOR AGREEMENT THIS AGREEMENT (the "Agreement") is made as of the 13th day of February 2014 and is by and between Islet Sciences, Inc., a Nevada corporation (hereinafter referred to as the "Company"), and Eric Barnett (hereinafter referred to as the "Director"). WHEREAS, it is essential to the Company to attract and retain accomplished and capable individuals

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2014 Islet Sciences, Inc.

Dr. Eric Barnett joins Islet Sciences, Inc. Board of Directors

Exhibit 99.1 Dr. Eric Barnett joins Islet Sciences, Inc. Board of Directors RALEIGH, North Carolina-(Marketwired – Jan 6, 2014) - Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors. “Dr. Barnett has deep experience in the life sciences industry and bri

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2014 Islet Sciences, Inc.

1

Exhibit 99.1 Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green RALEIGH, NC-(Marketwired - Dec 12, 2013) - Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) Dear Islet Shareholder, It is with great pleasure that I begin to communicate with our shareholders about the future of Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) (the "Company" or "Islet"). Dr. Wilkison, Islet's COO,

Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2013 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2013 TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2013 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 ————

1

Exhibit 10.3 1 2 3 4 5 6 7 8 9

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2013 Islet Sciences, Inc.

1

Exhibit 10.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

EX-10.2

Exhibit 10.2

1

Exhibit 10.5 1 2 3 4 5 6 7 8 9

EX-10.4

Exhibit 10.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2013 TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2013 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-34048 ———————

- NOTIFICATION OF LATE FILING

OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation Islet Sciences, Inc. Delaware DiaKine Therapeutics, Inc. Delaware

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34048 Islet Sciences, Inc. (Exact na

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 Islet Sciences, Inc.

- LATE FILING NOTICE

OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CONSULTING AGREEMENT

EXHIBIT 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made by and between Islet Sciences, Inc., a company organized and existing under the laws of the State of Nevada (hereinafter “COMPANY”), and John Steel, an individual residing in La Jolla, California (hereinafter “CONSULTANT”) effective as of July 1, 2013. WHEREAS, the CONSULTANT and COMPANY have entered into a Separ

Islet Sciences Begins Restructuring of Company’s Senior Management and Board of Directors Michael Earley is New Chairman and Chief Executive Officer, and Mark Foletta joins as Advisor to the CEO & Board

EXHIBIT 99.1 Islet Sciences Begins Restructuring of Company’s Senior Management and Board of Directors Michael Earley is New Chairman and Chief Executive Officer, and Mark Foletta joins as Advisor to the CEO & Board NEW YORK. NY, July 16, 2013 - Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people

SEPARATION AGREEMENT AND RELEASE

EXHIBIT 10.1 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE (this “Agreement”) is made by and between ISLET SCIENCES, INC., a Nevada corporation (“Company”), and JOHN STEEL (“Executive”) this 1st day of July, 2013 (“Effective Date”). Company and Executive are sometimes referred to collectively as the “Parties” or individually as a “Party”. PURPOSE Company and Executive have

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2013 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q o QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2013 o TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— o QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: ——————— Is

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2013 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2012 TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2012 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: ——————— Islet

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2012 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q Amendment No. 1 ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: ——————— Islet

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34048 Islet Scie

EMPLOYMENT AGREEMENT

EXHIBIT 10.5 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT is made and entered into as of the 1st day of March, 2012 (the “Agreement”), by and between ISLET SCIENCES, INC., a Nevada corporation (the “Company”), and Mr. John Steel (the “Executive”), (collectively the “Parties”). WITNESSETH: WHEREAS, on October 24, 2011, Islet Sciences, Inc., a Delaware corporation and a subsidiary of the Company,

Subsidiaries of the Registrant

EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation Islet Sciences, Inc. Delaware DiaKine Therapeutics, Inc. Delaware

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34048 Islet Sciences, Inc. (Exact na

1

EXHIBIT 3.3 1 2 3

CONSULTING AGREEMENT

EXHIBIT 10.6 CONSULTING AGREEMENT CONSULTING AGREEMENT, dated as of April 1, 2012, by and between RICHARD D. EGAN (the “Consultant”), having an address at , and ISLET SCIENCES, INC., a Nevada corporation (the “Company”), having offices at 1370 Avenue of the Americas, Suite 902, New York, New York 10019. 1. Relationship. The Consultant is hereby engaged by the Company to provide accounting and fina

1

EXHIBIT 4.6 1 2

1

EXHIBIT 3.1 1 2 3 4 5 6 7

1

EXHIBIT 3.2 1 2 3

WARRANT TO PURCHASE SHARES OF COMMON STOCK ISLET SCIENCES, INC. No. NST-1

EXHIBIT 4.5 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN M

AMENDED AND RESTATED BYLAWS ONE E-COMMERCE CORPORATION, INC. a Nevada corporation (THE "COMPANY") ARTICLE I

EXHIBIT 3.4 AMENDED AND RESTATED BYLAWS OF ONE E-COMMERCE CORPORATION, INC. a Nevada corporation (THE "COMPANY") ARTICLE I OFFICES Section 1.1 REGISTERED OFFICE. The registered office of the Company within the State of Nevada shall be located at either (i) the principal place of business of the Company in the State of Nevada or (ii) the office of the corporation or individual acting as the Company

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2012 Islet Sciences, Inc.

LONG-TERM SUPPLY AGREEMENT

EXHIBIT 10.1 LONG-TERM SUPPLY AGREEMENT THIS LONG-TERM SUPPLY AGREEMENT (the "Supply Agreement") is made effective as of the day of July, 2012 ("Effective Date"), by and between (“Supplier”), its principal place of business at ("Supplier"), and Islet Sciences, Inc., (“ISI”), a Nevada corporation, having its principal place of business at ("Buyer"). Recitals A. Buyer researches, develops, and comme

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2012 Islet Sciences, Inc.

Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2012 Islet Sciences, Inc.

Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2012 Islet Sciences, Inc.

Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2012 Islet Sciences, Inc.

Entry into a Material Definitive Agreement - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2012 Islet Sciences, Inc.

ISLET SCIENCES, INC. SUBSCRIPTION AGREEMENT

EXHIBIT 10.1 ISLET SCIENCES, INC. SUBSCRIPTION AGREEMENT As of , 2012 Mr. John Steel Chief Executive Officer Islet Sciences, Inc. 1370 Avenue of the Americas, Suite 902 New York, New York 10019 1. Subscription; Escrow Arrangement. (a) The undersigned subscriber (the “Subscriber”) hereby irrevocably subscribes for and agrees to purchase the number of shares (the “Shares”) of the Company’s common st

COMMON STOCK PURCHASE WARRANT

EXHIBIT 4.1 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THIS WARRANT SHALL NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION OF AN OFFER TO BUY THE SECURITIES IN ANY JUR

Entry into a Material Definitive Agreement - REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2012 Islet Sciences, Inc.

Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2012 Islet Sciences, Inc.

EX-4.1

Exhibit 4.1

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2012 Islet Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2012 TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2012 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: ——————— Islet

- CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2012 Islet Sciences, Inc.

LOCK-UP AGREEMENT

EXHIBIT 10.2 LOCK-UP AGREEMENT THIS AGREEMENT (this “Agreement”) is dated as of February, 2012 by and between One E-Commerce Corporation, a Nevada corporation (the “Company”), and (“Shareholder”). WHEREAS, the Company and Islet Sciences, Inc., a Delaware corporation, have entered into a share exchange agreement dated , 2012 (the “Share Exchange Agreement”) with DiaKine Therapeutics, Inc., a Delawa

SHARE EXCHANGE AGREEMENT by and among: ISLET SCIENCES, INC., a Delaware corporation ONE E-COMMERCE CORPORATION, a Nevada corporation DIAKINE THERAPEUTICS, INC., a Delaware corporation and STOCKHOLDERS OF DIAKINE THERAPEUTICS, INC. Dated as of Februar

EXHIBIT 10.1 SHARE EXCHANGE AGREEMENT by and among: ISLET SCIENCES, INC., a Delaware corporation ONE E-COMMERCE CORPORATION, a Nevada corporation DIAKINE THERAPEUTICS, INC., a Delaware corporation and STOCKHOLDERS OF DIAKINE THERAPEUTICS, INC. Dated as of February 23, 2012 TABLE OF CONTENTS 1 DESCRIPTION OF TRANSACTION 1 1.1 THE SHARE EXCHANGE. 1 1.2 CAPITALIZATION. 1 1.3 CLOSING. 2 1.4 TAX CONSEQ

- DEFINITIVE INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: o Preliminary Information Statement þ Definitive Information Statement o Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) One E-Commerce Corporation (Name of Registrant as

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2012 One E-Commerce Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.

January 26, 2012

Exhibit 16.1 January 26, 2012 Office of the Chief Accountant Securities and Exchange Commission 100F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements included under Item 4.01 in the Form 8-K dated January 27, 2012 of One E-Commerce Corporation (the "Company") to be filed with the Securities and Exchange Commission and we agree with such statements insofar as they relat

- PRELIMINARY INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: þ Preliminary Information Statement o Definitive Information Statement o Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) One E-Commerce Corporation (Name of Registrant as

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2012 One E-Commerce Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.

Islet Sciences Signs Cell Therapy Alliance and Service Agreement with Progenitor Cell Therapy Will support development and commercialization of novel therapy for treatment of diabetes

EXHIBIT 99.1 Islet Sciences Signs Cell Therapy Alliance and Service Agreement with Progenitor Cell Therapy Will support development and commercialization of novel therapy for treatment of diabetes New York, NY (January 12, 2012) –Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTC.BB : ONCE) a biotechnology company engaged in the research, development and commerciali

EX-10.1

EXHIBIT 10.1

-

ONE E-COMMERCE CORPORATION 1370 Avenue of the Americas, Suite 902 New York, New York 10019 Tel.

1

EXHIBIT 4.1 1 2 3 4 5 6 7

AGREEMENT AND PLAN OF MERGER

EXHIBIT 2.2 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (“Plan” or “Merger Agreement”) dated as of December 30, 2011 by and among One E-Commerce Corporation, a Nevada corporation (“Parent”), ONCE, Inc., a Delaware corporation (“Merger Sub”), which is a wholly owned subsidiary of Parent, and Islet Sciences, Inc., a Delaware corporation (“ISI”). Merger Sub and ISI are hereinafter

Subsidiaries of the Registrant

EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation Islet Sciences, Inc. Delaware

1

EXHIBIT 2.1 1 2

STOCK PURCHASE AGREEMENT

EXHIBIT 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this "Agreement") is made and entered into as of September 15, 2011 by and between Mr. John Welch (the "Seller"), 1 Clyde Street, Golf, Illinois 60029, and Islet Sciences, Inc., a Delaware corporation (the "Purchaser"). WHEREAS, the Seller is the sole record and beneficial owner of (a) 9,902,180 shares (the "Shares") of common st

1

EXHIBIT 4.2 1 2 3 4 5 6 7

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2011 Commission File Number: 001-34048 One E-Commerce Corporation (Exact name of registrant as specified in its charter) Nevada 87-0531751 (State or other jurisdiction of

-

ONE E-COMMERCE CORPORATION 1370 Avenue of the Americas, Suite 902 New York, New York 10019 Tel.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2011 ¨ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-3404

-

ONE E-COMMERCE CORPORATION 1370 Avenue of the Americas, Suite 902 New York, New York 10019 Tel.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. _) One E-Commerce Corporation (Name of Issuer) COMMON STOCK, PAR VALUE $.001 PER SHARE (Title of Class of Secu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2011 One E-Commerce

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2011 One E-Commerce Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2011 One eCommerce Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER One eCommerce Corporation (Name of Registrant as Specified in it

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER One eCommerce Corporation (Name of Registrant as Specified in its Charter) Nevada 001-34048 87-0531751 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One C

One eCommerce

One eCommerce One Clyde Street, Box 83 Golf, Ill 60029 C o r p o r a t i o n Harry A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2011 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185 —————

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 SEC FILE NUMBER FORM 12b-25 CUSIP NUMBER NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K ý Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2011 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185 ————

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-K ??????? ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended: December 31, 2010 ??????? One eCommerce Corporation (Name of small business issuer in its charter) ??????? Nevada 1-10185 87-0531751 (State or Other Jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2010 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2010 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2010 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185 —————

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2010 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2010 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185 One

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— ý ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended: December 31, 2009 ——————— One eCommerce Corporation (Name of small business issuer in its charter) ——————— Nevada 1-10185 87-0531751 (State or Other Jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2009 ¨ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2009 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2009 ¨ TRANSITION REPORT PURSUANT TO

United States Securities & Exchange Commission EDGAR Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2009 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2009 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 1-10185 ————

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended: December 31, 2008 One e Commerce Corporation (Name of small

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— ý ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended: December 31, 2008 ——————— One e Commerce Corporation (Name of small business issuer in its charter) ——————— Nevada 1-10185 87-0531751 (State or Other Jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in it

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in its charter) Nevada 87-0531751 (State of incorporation) (Employer IRS Number) One Clyde Street, Golf, Illinois, 60029-0083 (Address of principal executi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in it

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in its charter) Nevada 87-0531751 (State of incorporation) (Employer IRS Number) One Clyde Street, Golf, Illinois, 60029-0083 (Address of principal executi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10 General Form for Registration of Securities of Small Business Issuers under Section 12(b) or (g) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10 General Form for Registration of Securities of Small Business Issuers under Section 12(b) or (g) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in its charter) Nevada 87-0531751 (State of incorporation) (Employer IRS Number) One Clyde Street, Golf, Illinois, 60029-0083 (Address of principal executive offices) (Zip Code) (312) 983-8980 (Registrant's telephone number) Securities to be registered under Section 12(b) of the Exchange Act: NONE Securities to be registered under Section 12(g) of the Exchange Act: Common Stock: $0.

One eCommerce

One Clyde Street, Box 83 Golf, Ill 60029 One eCommerce Harry Nass President C o r p o r a t i o n May 8, 2009 VIA OVERNIGHT DELIVERY AND BY EDGAR Securities and Exchange Commission 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10 General Form for Registration of Securities of Small Business Issuers under Section 12(b) or (g) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10 General Form for Registration of Securities of Small Business Issuers under Section 12(b) or (g) of the Securities Exchange Act of 1934 One e Commerce Corporation (Exact name of small business issuer as specified in its charter) Nevada 87-0531751 (State of incorporation) (Employer IRS Number) One Clyde Street, Golf, Illinois, 60029-0083 (Address of principal executive offices) (Zip Code) (312) 983-8980 (Registrant's telephone number) Securities to be registered under Section 12(b) of the Exchange Act: NONE Securities to be registered under Section 12(g) of the Exchange Act: Common Stock: $0.